Daiichi Sankyo and UCSF to Collaborate over Neurodegenerative Drug Discovery and Development

Tokyo, Japan, based Daiichi Sankyo has entered into a drug-discovery partnership with University of California, San Francisco (UCSF) to develop new therapies for neurodegenerative diseases. The partnership aims to leverage Daiichi’s drug development expertise and UCSF’s world-renown neurobiologists and focuses on drug discovery and development of diagnostics for neurodegenerative diseases, including Parkinson’s disease, Creutzfeldt-Jakob disease and Alzheimer’s disease. Daiichi Sankyo brings their compound library to the table, allowing for high-throughput drug screening using technology developed at UCSF. Daiichi will provide research funding as well as royalties and milestone payments for commercially successful products developed under the collaboration.

Tokyo, Japan, based Daiichi Sankyo has entered into a drug-discovery partnership with University of California, San Francisco (UCSF) to develop new therapies for neurodegenerative diseases. The partnership aims to leverage Daiichi’s drug development expertise and UCSF’s world-renown neurobiologists and focuses on drug discovery and development of diagnostics for neurodegenerative diseases, including Parkinson’s disease, Creutzfeldt-Jakob disease and Alzheimer’s disease. Daiichi Sankyo brings their compound library to the table, allowing for high-throughput drug screening using technology developed at UCSF. Daiichi will provide research funding as well as royalties and milestone payments for commercially successful products developed under the collaboration.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail